VivoSeq
Other

Remifentanil

0

Pipeline Programs

1

Active Trials

0

Companies Involved

Remifentanil is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

95/100

Attrition Rate

4/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

67

clinical trials

Completed54 · 81%
Unknown status9 · 13%
Terminated2 · 3%
Recruiting1 · 1%
Withdrawn1 · 1%

Trial Activity

67 trials

Remifentanil and Stress Hormones Response
Completed··N/A·NCT03378674·50 enrolled
EC95 of Remifentanil for Preventing Cough
Completed··N/A·NCT02973724·40 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)